Compare TDY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDY | MRNA |
|---|---|---|
| Founded | 1960 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 26.7B |
| IPO Year | 2000 | 2018 |
| Metric | TDY | MRNA |
|---|---|---|
| Price | $650.94 | $79.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $693.71 | $34.27 |
| AVG Volume (30 Days) | 302.0K | ★ 8.0M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.70 | ★ 21.77 |
| EPS | ★ 4.85 | N/A |
| Revenue | $1,020,400,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $5.54 | $9.36 |
| Revenue Next Year | $5.08 | $15.43 |
| P/E Ratio | $134.54 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $483.02 | $22.28 |
| 52 Week High | $693.38 | $81.40 |
| Indicator | TDY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.05 | 79.87 |
| Support Level | $627.29 | $45.69 |
| Resistance Level | $679.74 | N/A |
| Average True Range (ATR) | 18.49 | 5.44 |
| MACD | 5.08 | 2.10 |
| Stochastic Oscillator | 67.27 | 95.25 |
Teledyne Technologies Inc provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. The firm operates in four segments: Digital Imaging, Instrumentation, Aerospace and Defense Electronics, and Engineered Systems. The Digital Imaging segment, that derives maximum revenue, includes high-performance sensors, cameras and systems, within the visible, infrared and X-ray spectra for use in industrial, government and medical applications, as well as MEMS and high-performance, high-reliability semiconductors including analog-to-digital and digital-to-analog converters. Geographically, the company operates in United States, Europe, Asia, and All other.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.